Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.79 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HMGCR | P04035 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 3/20 | 0.39 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL10520117 | 1.00 | ALDH1A1 (0.79) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| Citric Acid SCHEMBL15779277 | 1.00 | ALDH1A1 (0.79) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| Citric Acid SCHEMBL73266 | 1.00 | ALDH1A1 (0.79) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| Citric Acid SCHEMBL27647752 | 1.00 | ALDH1A1 (0.79) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| Citric Acid SCHEMBL23012587 | 0.97 | ALDH1A1 (0.75) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| Citric Acid SCHEMBL10962662 | 0.97 | ALDH1A1 (0.75) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| Citric Acid SCHEMBL11531681 | 0.97 | ALDH1A1 (0.75) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| Citric Acid SCHEMBL6131060 | 0.97 | ALDH1A1 (0.75) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| Citric Acid SCHEMBL9333028 | 0.97 | ALDH1A1 (0.75) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| Citric Acid SCHEMBL15653350 | 0.97 | ALDH1A1 (0.75) | ALDH1A1TSHRLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105530998-B | Oral cavity composition | 3M创新有限公司 | 2018-09-21 | — | — | CN | claimed |
| CN-105530998-A | Oral compositions | 3M INNOVATIVE PROPERTIES CO | 2016-04-27 | — | — | CN | claimed |
| CN-105530998-B | Oral cavity composition | 3M创新有限公司 | 2018-09-21 | — | — | CN | disclosed |
| CN-105530998-A | Oral compositions | 3M INNOVATIVE PROPERTIES CO | 2016-04-27 | — | — | CN | disclosed |
| US-8486617-B2 | Methods for preparing freeze-dried platelets, compositions comprising freeze-dried platelets, and methods of use | Cellphirc, Inc (US) | 2013-07-16 | — | — | US | disclosed |
| US-8097403-B2 | Determining clotting capability of fresh blood and/or blood components using lypholized blood products | CELLPHIRE, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| CN-101072506-B | Methods for preparing freeze-dried platelets, compositions comprising freeze-dried platelets, and methods of use | CELLPHIRE INC | 2010-05-12 | — | — | CN | disclosed |
| EP-1784639-B1 | METHODS FOR PREPARING FREEZE-DRIED PLATELETS, COMPOSITIONS COMPRISING FREEZE-DRIED PLATELETS, AND METHODS OF USE | CELLPHIRE INC (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20080145834-A1 | FREEZE-DRIED PLATELETS AS A DIAGNOSTIC AGENT | CELLPHIRE, INC. | 2008-06-19 | — | — | US | disclosed |
| CN-101072506-A | Methods for preparing freeze-dried platelets, compositions comprising freeze-dried platelets, and methods of use | ADLYFE INC (US) | 2007-11-14 | — | — | CN | disclosed |
| US-20070243178-A1 | Methods for Preparing Freeze-Dried Platelets, Compositions Comprising Freeze-Dried Platelets, and Methods of Use | CELLPHIRE, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20060051731-A1 | Processes for preparing lyophilized platelets | CELLPHIRE, INC. | 2006-03-09 | — | — | US | disclosed |
| US-5736313-A | Method of lyophilizing platelets by incubation with high carbohydrate concentrations and supercooling prior to freezing | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1998-04-07 | — | — | US | disclosed |
| US-5690963-A | Freeze dried red blood cells | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1997-11-25 | — | — | US | disclosed |
| US-4871442-A | ELECTROCONDUCTIVE LAYER, REDOX LAYER, BARRIER LAYER, ION SELECTIVE LAYER | TERUMO CORPORATION (JP) | 1989-10-03 | — | — | US | disclosed |